Hirudin causes more bleeding than heparin in a rabbit ear bleeding model

Area of Science:

• Pharmacology
• Hematology
• Biochemistry

Background:

• Current practices often use activated partial thromboplastin time (APTT) to guide anticoagulant dosing.
• Hirudin is a direct thrombin inhibitor with a different pharmacokinetic and pharmacodynamic profile than heparin.
• The appropriateness of using APTT for hirudin dose selection requires investigation.

Purpose of the Study:

• To evaluate the suitability of activated partial thromboplastin time (APTT) for selecting hirudin doses.
• To compare the bleeding effects of hirudin and heparin in relation to APTT.
• To assess the responsiveness of APTT, thrombin clotting time (TCT), and factor Xa clotting time to hirudin and heparin.

Main Methods:

• A rabbit bleeding ear model was employed to assess bleeding.
• Various doses of heparin and hirudin were administered.
• The relationship between APTT, TCT, factor Xa clotting time, and bleeding was analyzed.

Main Results:

• Both heparin and hirudin demonstrated a dose-dependent increase in bleeding.
• Hirudin caused a significantly greater increase in bleeding than heparin for equivalent increases in the APTT ratio within the therapeutic range (1.5–2.5).
• Thrombin clotting time (TCT) showed greater responsiveness to hirudin-induced bleeding compared to APTT and factor Xa clotting time.

Conclusions:

• Extrapolating monitoring practices from heparin to new antithrombotics like hirudin can be misleading.
• The activated partial thromboplastin time (APTT) may not be the optimal test for monitoring hirudin therapy.
• Thrombin clotting time (TCT) may offer a more sensitive measure for monitoring hirudin's anticoagulant effects and associated bleeding risk.